Shifting the lines against central nervous system disorders

« A disruptive technology, which can be applied in the treatment of numerous conditions »

Declaration of total number of shares and voting rights

Dowload PDF File (272Ko)

THERANEXUS reports cash position as of December 31, 2019

Télécharger le PDF (349Ko)

THERANEXUS announces its financial calendar for 2020

Download PDF File (276Ko)

THERANEXUS announces the clinical results of its phase 1b study demonstrating the extended pharmacological profile of its drug candidate THN201 compared to donepezil

Download PDF File (381 Ko)